

Three Things You Should Know About ... Karl von Mangoldt

Prior to co-founding Protembis, Karl was an investment banker at Barclays Corporate and Investment Banking, London. He co-founded Protembis along with Conrad Rasmus, also an investment banker. Karl and Conrad are Co-CEOs of Protembis.

1 KARL IS PASSIONATE ABOUT MEDICINE.

"I wanted to study medicine, that was my fascination from the start of my young-adult life," says Karl. "I certainly have no regrets about beginning my career as a banker. It has given me the skills and experience and relationships that have been intrinsic to the successful start-up of Protembis. Investment banking is a very good training ground. You learn you are capable of working much much harder than you ever thought you were capable of working: meaning day and night and weekends and all the time. It also demands laser focus and pinpoint accuracy. Nevertheless, I had always loved the natural sciences such as biology and chemistry and physics. I also happened to have a dear friend who is an entrepreneurial-minded cardiologist with a keen mindset for advancing medicine. Over time, I became convinced that I could make the concept of a cerebral protection system for interventional procedures real, and thus Protembis was born."

2 KARL IS ANALYTICAL BY NATURE.

"I am very numeric focused." says Karl. Prior to his co-founding of Protembis with Co-CEO Conrad Rasmus, Karl was an investment banker at Barclays Capital in London, specializing in strategic equity derivatives with equity-linked originations. "When you consider that my partner and Protembis co-founder Conrad Rasmus was also an investment banker prior to starting Protembis with me, between the two of us we were convinced that we could get the necessary funding and put a strong team in place to build a great Company that would make a big difference in patients' lives. It proved to be a big early advantage for us that Conrad and I both had a financial background with a strong network to get Protembis started. Combined with our CTO Ollie Schumacher, who co-founded CircuLite, we were able to attract an extraordinary combination of people to work for, or otherwise become involved with, the Company right from the start," says Karl.



Karl von Mangoldt
Co-CEO, Protembis

3 KARL IS AN EXPERT ON EPDs.

"As a next-gen embolic protection device, ProtEmbo® offers numerous compelling advantages over currently marketed EPDs," says Karl. "First, it is designed to be the simplest device for cardiologists and surgeons to use, making rapid deployment possible. And, because it is cost-effective to manufacture, ProtEmbo will be competitively priced. In addition, ProtEmbo is designed to be consistently stable *and* is able to deflect the tiniest of debris, down to 60 microns, compared to the competition's deflection or capture rates, which range from 125 to 170 microns in size. ProtEmbo is a potential blockbuster device."

